Lung Cancer

Improved progression-free survival and overall survival in patients who received upfront stereotactic radiotherapy and TKI treatment should prompt additional study.

Previously untreated patients and those who had received prior intracranial radiotherapy responded to selpercatinib treatment.

Treatment was well tolerated and also associated with delayed progression in previously treated patients with NSCLC and MET^Amp/Ex14Δ.

Dual treatment with ramucirumab and erlotinib produced similar results in patients with ex21 and ex19 mutations.

This study reports on the ZENITH20-2 cohort of previously treated patients with advanced NSCLC and an HER2 exon 20 insertion mutation.

Savolitinib had promising antitumor activity in patients with METex14+ NSCLC and showed acceptable tolerability.

First-line treatment with osimertinib in patients with EGFR-mutated is associated with longer overall survival compared with other drugs in its class.

Researchers presented updated 5-year progression-free survival and overall survival data from a clinical trial evaluating the efficacy and safety of alectinib versus crizotinib in previously untreated patients with ALK-positive NSCLC.

Treatment with combination apatinib and gefitinib is associated with improved progression-free survival compared with treatment with gefitinib alone in patients with NSCLC and EGFR mutations.

A phase 1 clinical trial of the HER3-directed antibody–drug conjugate patritumab deruxtecan shows potential for treating patients with EGFR-mutated NSCLC.